H M Faddy1,2, J J Fryk3, D Watterson4, P R Young4, N Modhiran4, D A Muller5, S D Keil6, R P Goodrich6, D C Marks7. 1. Research and Development, Australian Red Cross Blood Service, Brisbane, Qld, Australia. hfaddy@redcrossblood.org.au. 2. School of Medicine, University of Queensland, Brisbane, Qld, Australia. hfaddy@redcrossblood.org.au. 3. Research and Development, Australian Red Cross Blood Service, Brisbane, Qld, Australia. 4. Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Qld, Australia. 5. Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Qld, Australia. 6. Terumo BCT, Lakewood, CO, USA. 7. Research and Development, Australian Red Cross Blood Service, Sydney, NSW, Australia.
Abstract
BACKGROUND: Dengue viruses (DENV 1-4) are emerging across the world, and these viruses pose a risk to transfusion safety. Pathogen inactivation may be an alternative approach for managing the risk of DENV transfusion transmission. This study aimed to investigate the ability of riboflavin and UV light to inactivate DENV 1-4 in platelet concentrates. MATERIALS AND METHODS: DENV 1-4 were spiked into buffy coat-derived platelet concentrates in additive solution (SSP+) before being treated with riboflavin and UV light. Infectious virus was quantified pre- and posttreatment, and the reduction in viral infectivity was calculated. RESULTS: All four DENV serotypes were modestly reduced after treatment. The greatest amount of reduction in infectivity was observed for DENV-4 (1·81 log reduction) followed by DENV-3 (1·71 log reduction), DENV-2 (1·45 log reduction) and then DENV-1 (1·28 log reduction). CONCLUSION: Our study demonstrates that DENV 1-4 titres are modestly reduced following treatment with riboflavin and UV light. With the increasing number of transfusion-transmitted cases of DENV around the globe, and the increasing incidence and geographical distribution of DENV, additional approaches for maintaining blood safety may be required in the future.
BACKGROUND:Dengue viruses (DENV 1-4) are emerging across the world, and these viruses pose a risk to transfusion safety. Pathogen inactivation may be an alternative approach for managing the risk of DENV transfusion transmission. This study aimed to investigate the ability of riboflavin and UV light to inactivate DENV 1-4 in platelet concentrates. MATERIALS AND METHODS: DENV 1-4 were spiked into buffy coat-derived platelet concentrates in additive solution (SSP+) before being treated with riboflavin and UV light. Infectious virus was quantified pre- and posttreatment, and the reduction in viral infectivity was calculated. RESULTS: All four DENV serotypes were modestly reduced after treatment. The greatest amount of reduction in infectivity was observed for DENV-4 (1·81 log reduction) followed by DENV-3 (1·71 log reduction), DENV-2 (1·45 log reduction) and then DENV-1 (1·28 log reduction). CONCLUSION: Our study demonstrates that DENV 1-4 titres are modestly reduced following treatment with riboflavin and UV light. With the increasing number of transfusion-transmitted cases of DENV around the globe, and the increasing incidence and geographical distribution of DENV, additional approaches for maintaining blood safety may be required in the future.
Authors: Vincent C C Cheng; Siddharth Sridhar; Shuk-Ching Wong; Sally C Y Wong; Jasper F W Chan; Cyril C Y Yip; Chi-Hung Chau; Timmy W K Au; Yu-Yan Hwang; Carol S W Yau; Janice Y C Lo; Cheuk-Kwong Lee; Kwok-Yung Yuen Journal: Emerg Infect Dis Date: 2018-01-17 Impact factor: 6.883
Authors: R A Akasov; N V Sholina; D A Khochenkov; A V Alova; P V Gorelkin; A S Erofeev; A N Generalova; E V Khaydukov Journal: Sci Rep Date: 2019-07-04 Impact factor: 4.379
Authors: Alberto A Amarilla; Naphak Modhiran; Yin Xiang Setoh; Nias Y G Peng; Julian D J Sng; Benjamin Liang; Christopher L D McMillan; Morgan E Freney; Stacey T M Cheung; Keith J Chappell; Alexander A Khromykh; Paul R Young; Daniel Watterson Journal: Front Microbiol Date: 2021-02-12 Impact factor: 5.640
Authors: Kelly Rooks; Clive R Seed; Jesse J Fryk; Catherine A Hyland; Robert J Harley; Jerry A Holmberg; Denese C Marks; Robert L P Flower; Helen M Faddy Journal: J Blood Transfus Date: 2016-11-13